REPL

Replimune Group, Inc.

8.49 USD
-0.01 (-0.12%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Replimune Group, Inc. stock is up 50% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 83.33% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer.

  • Barclays
    Fri Jun 7, 14:02
    buy
    confirm
  • HC Wainwright & Co.
    Fri Jun 7, 07:13
    buy
    confirm